Targeted IL-1 blockers and CMR techniques allow more-tailored treatment strategies
Phase 3 study may lead to first FDA approval for the indication
Anakinra and rilonacept show dramatic reductions in recurrence rates
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy